NCT07366112 CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment Status NOT_YET_RECRUITING Phase PHASE2
NCT07294339 A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast Cancer Status NOT_YET_RECRUITING Phase NA
NCT07264998 Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea Status RECRUITING Phase N/A
NCT07073755 Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd Status RECRUITING Phase N/A
NCT06970912 ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer Status RECRUITING Phase PHASE2
NCT06878248 A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT06805812 Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study Status RECRUITING Phase N/A
NCT06570031 ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT06518837 Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer Status RECRUITING Phase PHASE2
NCT05766410 A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC Status RECRUITING Phase PHASE2
NCT05651087 Evaluate Efficacy and Safety of LACUDY for Improving Vaginal Environment in Breast Cancer Patient Status UNKNOWN Phase NA
NCT05573126 Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer Status RECRUITING Phase PHASE1/PHASE2
NCT05524584 Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer Status RECRUITING Phase PHASE2
NCT05503108 Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer Status SUSPENDED Phase PHASE3
NCT05467891 Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer Status RECRUITING Phase PHASE2
NCT05452213 Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients Status RECRUITING Phase PHASE4
NCT05165225 Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial Status ACTIVE_NOT_RECRUITING Phase PHASE2